Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:06:25.217Z.
Calculation as of: 2026-10-06T14:06:25.217Z.
Quote observation: 2026-10-06T14:02:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4a3a0e03002c1ec33ed026058caacdcc2374dd3411b27b5cd001974e391cfa1f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$38.60M
EBITDA Yield
9.49%
TTM Avg
10.40%
3Y Avg
3.98%
5Y Avg
3.32%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | $37.81M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.60M | 9.49% | 10.40% | 3.98% | 3.32% |
| Incannex Healthcare Limited (IXHL)vs › | $38.82M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $36.70M | N/A | 15.63% | 9.19% | 7.93% |
| Accuray Incorporated (ARAY)vs › | $37.14M | N/A | 4.27% | 2.75% | 3.74% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $36.45M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.32M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $35.82M | N/A | N/A | N/A | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.44M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
